Myriad Pharmaceuticals Private Limited
Wholesale trading of pharmaceutical products and medical goods since 2011.
2011 | Nagpur, Maharashtra (India) | Active
Myriad Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 12.45%
- Profit Growth 3.53%
- Ebitda 43.35%
- Net Worth 28.42%
- Total Assets -1.64%
About Myriad Pharmaceuticals
Myriad Pharmaceuticals Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 September 2011 and has a history of 13 years and five months. Its registered office is in Nagpur, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Dhanraj Mohod, Govinda Mohod, Snehal Sonkusare, and Two other members serve as directors at the Company.
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100MH2011PTC221866
- Company No.
221866
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Sep 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Pharma
Who are the key members and board of directors at Myriad Pharmaceuticals?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dhanraj Mohod  | Director | 11-Sep-2011 | Current |
| Govinda Mohod | Director | 11-Sep-2011 | Current |
| Snehal Sonkusare | Director | 08-Feb-2020 | Current |
| Ashish Prachand | Director | 10-Nov-2020 | Current |
| Pralhad Sharma | Director | 10-Nov-2020 | Current |
Financial Performance of Myriad Pharmaceuticals.
Myriad Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.45% increase. The company also saw a slight improvement in profitability, with a 3.53% increase in profit. The company's net worth Soared by an impressive increase of 28.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Myriad Pharmaceuticals?
In 2023, Myriad Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Myriad Pharmaceuticals?
Unlock and access historical data on people associated with Myriad Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Myriad Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Myriad Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.